Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a radioactive tracer and MRI reveal prostate Cancer's true extent?

NCT ID NCT04053842

Diagnosis Sponsor: Glenn Bauman Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a combination of PET scans with a radioactive tracer called [18F]PSMA-1007, sodium MRI, and multiparametric MRI can accurately predict where prostate cancer is and how aggressive it is. The study enrolls men who are scheduled to have their prostate removed as standard treatment. Before surgery, participants undergo these imaging scans. After surgery, researchers compare the scan results with the actual cancer found in the removed prostate to see how well the imaging predicted the disease. The goal is to build a model that helps doctors identify cancer lesions more reliably.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]PSMA-1007, a radioactive tracer given by injection for PET imaging
What this could lead to
If the imaging models work, doctors could map prostate cancer more precisely before surgery, which may help plan treatment and avoid missing aggressive tumors.
What could go wrong
This is a small Phase 2 study of 16 men, so the models may not hold up in larger or more diverse groups. Imaging can also miss small tumors or show false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

16 people

The number who actually took part.

Started

Feb 2021

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of informed consent for this study * Male, aged 18 years or older * Pathologically confirmed prostate cancer on previous biopsy * Suitable for and consenting to Radical Prostatectomy for treatment as standard of care Exclusion Criteria: * Prior therapy for prostate cancer (including hormone therapy) * Use of 5-alpha reductase inhibitors, i.e. finasteride (Proscar) or dutasteride (Avodart) within 6 months of study start. Patients undergoing a 6-month washout period prior to study start will be eligible. * Inability to comply with the pre-operative imaging panel * Patients scheduled for radical prostatectomy with prostate size exceeding 65 cc * Allergy to contrast agents to be used as part of the imaging panel * Acute kidney injury (AKI), chronic kidney disease (CKD) Stage 4 or 5 (estimated Glomerular Filtration Rate \[eGFR\] \< 30 mL/min/1.73m2) or those on dialysis * Post-void residual urine volume \> 150 cc (determined by post-void ultrasound) * Hip prosthesis, vascular grafting that is MRI incompatible or sources of artefact within the pelvis * Contraindication to MRI * pacemaker or other electronic implants * known metal in the orbit * cerebral aneurysm clips

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate adenocarcinoma Prostate cancer Prostate neoplasm

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.